Usana Health Sciences (FRA:USJ) Cyclically Adjusted Revenue per Share: €49.71 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:USJ Usana Health Sciences Inc FRA:USJ
60 GF Score
Price €12.70
GF Value €29.41
! 5 Warning Signs
View Full Analysis

What is Usana Health Sciences Cyclically Adjusted Revenue per Share?

Usana Health Sciences FRA:USJ +2.42% 60 Cyclically Adjusted Revenue per Share is €49.71 as of Jun. 2026. GuruFocus rates FRA:USJ with a GF Score™ of 60/100 and a GF Value™ of €29.41. The stock has 5 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Usana Health Sciences's adjusted revenue per share for the three months ended in Jun. 2026 was €10.388. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is €49.71 for the trailing ten years ended in Jun. 2026.

During the past 12 months, Usana Health Sciences's average Cyclically Adjusted Revenue Growth Rate was 3.20% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 4.50% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 8.00% per year. During the past 10 years, the average Cyclically Adjusted Revenue Growth Rate was 11.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Usana Health Sciences was 26.80% per year. The lowest was 4.50% per year. And the median was 14.90% per year.

As of today (2026-09-15), Usana Health Sciences's current stock price is €12.70. Usana Health Sciences's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 was €49.71. Usana Health Sciences's Cyclically Adjusted PS Ratio of today is 0.26.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Usana Health Sciences was 4.53. The lowest was 0.23. And the median was 2.03.


Usana Health Sciences  (FRA:USJ) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Usana Health Sciences's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=12.70/49.71
=0.26

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Usana Health Sciences was 4.53. The lowest was 0.23. And the median was 2.03.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Usana Health Sciences Cyclically Adjusted Revenue per Share Related Terms


Usana Health Sciences Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Usana Health Sciences's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Usana Health Sciences Cyclically Adjusted Revenue per Share Chart

Usana Health Sciences Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 39.16 46.50 47.66 51.83 47.99

Usana Health Sciences Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 48.78 47.35 47.99 48.65 49.71

FRA:USJ vs NATR, BYND, BGS: Cyclically Adjusted Revenue per Share Comparison

For the Packaged Foods subindustry, Usana Health Sciences's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Usana Health Sciences Cyclically Adjusted PS Ratio vs Consumer Packaged Goods Industry

For the Consumer Packaged Goods industry and Consumer Defensive sector, Usana Health Sciences's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Usana Health Sciences's Cyclically Adjusted PS Ratio falls into.


FRA:USJ
60GF Score
Usana Health Sciences Inc FRA:USJ
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Usana Health Sciences Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Usana Health Sciences's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=10.388/333.9520*333.9520
=10.388

Current CPI (Jun. 2026) = 333.9520.

Usana Health Sciences Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201609 9.093 241.428 12.578
201612 9.708 241.432 13.428
201703 9.591 243.801 13.137
201706 9.337 244.955 12.729
201709 9.071 246.819 12.273
201712 9.661 246.524 13.087
201803 9.788 249.554 13.098
201806 10.186 251.989 13.499
201809 10.205 252.439 13.500
201812 10.716 251.233 14.244
201903 10.048 254.202 13.200
201906 9.749 256.143 12.710
201909 10.547 256.759 13.718
201912 11.266 256.974 14.641
202003 11.230 258.115 14.529
202006 11.131 257.797 14.419
202009 12.072 260.280 15.489
202012 12.292 260.474 15.759
202103 12.120 264.877 15.281
202106 13.676 271.696 16.810
202109 11.547 274.310 14.058
202112 11.887 278.802 14.238
202203 12.486 287.504 14.503
202206 12.896 296.311 14.534
202209 12.031 296.808 13.537
202212 11.609 296.797 13.062
202303 11.976 301.836 13.250
202306 11.266 305.109 12.331
202309 10.124 307.789 10.985
202312 10.680 306.746 11.627
202403 10.874 312.332 11.627
202406 10.320 314.175 10.970
202409 9.551 315.301 10.116
202412 10.482 315.605 11.091
202503 12.423 319.799 12.973
202506 11.226 322.561 11.622
202509 9.995 324.800 10.277
202512 10.631 324.054 10.956
202603 11.617 330.213 11.749
202606 10.388 333.952 10.388

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of €49.71 mean?
Usana Health Sciences (FRA:USJ) has a Cyclically Adjusted Revenue per Share of €49.71 as of Jun. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Usana Health Sciences and its competitors.
Is Usana Health Sciences' Cyclically Adjusted Revenue per Share too high?
Usana Health Sciences' current Cyclically Adjusted Revenue per Share is €49.71. Overall, Usana Health Sciences has a GF Score™ of 60/100, reflecting its overall financial health beyond just this single metric.
How does Usana Health Sciences' Cyclically Adjusted Revenue per Share compare to NATR and BYND?
Usana Health Sciences' Cyclically Adjusted Revenue per Share of €49.71 can be compared against companies in the Consumer Packaged Goods industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Consumer Packaged Goods company?
A good Cyclically Adjusted Revenue per Share depends on the Consumer Packaged Goods industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Usana Health Sciences and its competitors. Usana Health Sciences's current Cyclically Adjusted Revenue per Share is €49.71. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Usana Health Sciences stock overvalued right now?
Usana Health Sciences (FRA:USJ) has a current Cyclically Adjusted Revenue per Share of €49.71. The stock's GF Value™ is €29.41, compared to a current price of €12.70 — trading 56.8% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is €49.71. Usana Health Sciences' overall GF Score™ is 60/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Usana Health Sciences (FRA:USJ), the current Cyclically Adjusted Revenue per Share is €49.71 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Usana Health Sciences (FRA:USJ) Overvalued in 2026?

Based on GuruFocus' analysis, Usana Health Sciences stock appears to be undervalued. The current stock price of €12.70 is trading 56.8% below its estimated GF Value™ of €29.41.

Key valuation signals for FRA:USJ:

  • Cyclically Adjusted Revenue per Share: €49.71
  • GF Value™: €29.41 vs. price of €12.70 (56.8% below fair value)
  • GF Score™: 60/100 with 5 warning signs

No single metric tells the full story. See the FRA:USJ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Usana Health Sciences Business Description

Other Exchanges USNA:USA
Address 3838 West Parkway Boulevard, Salt Lake City, UT, USA, 84120
Usana Health Sciences Inc develops and manufactures high-quality nutritional supplements, functional foods, and personal care products that are sold throughout the world. The company has developed and manufactured high-quality, science-based nutritional, personal care, and skincare products with a primary focus on promoting long-term health and wellness. The Company's reporting units for goodwill purposes are tied to its reportable segments: Core nutritional and Hiya direct-to-consumer. The core nutritional segment consists of three individual reporting units that are determined based on the operational nature of the business: Buy-Sell, China, and India. Geographically, it is in Asia Pacific, the Americas, and Europe. With the majority of revenue from Asia Pacific(Greater China).
60GF Score

Get the complete analysis for FRA:USJ

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€12.70
Price
€29.41
GF Value